Amgen says EU CHMP backs broader Repatha use to cut first heart attack, stroke risk
Reuters2026/07/30 12:35- EMA’s CHMP backed expanding Repatha’s EU use to adults with established atherosclerotic cardiovascular disease or high risk to cut LDL-C.
- Opinion was supported by the Phase 3 VESALIUS-CV trial in more than 12,000 high-risk patients without prior heart attack or stroke.
- Trial showed a 25% relative risk reduction in a composite of coronary death, myocardial infarction, or ischemic stroke versus placebo.
- European Commission decision is expected in the coming months.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nvidia quietly reduces OpenAI data center guarantee from 250 billions to below 120 billions
Nvidia and OpenAI are close to signing a data center financing agreement in Ohio. However, Nvidia's financial guarantee has been reduced from $250 billion to less than $120 billion, covering only about 5 GW of computing power for the project's first phase. This adjustment is a direct response to investor concerns about Nvidia's risk exposure—after the previous $250 billion guarantee plan was revealed, Nvidia's stock price fell 5% in a single day. The agreement could be signed as early as this weekend.

Ivy League’s space gamble: Harvard reveals $2.2 billions SpaceX position, its largest single stock holding
Harvard University Investment Management Company disclosed that it holds $2.2 billion worth of SpaceX shares, making it the largest single stock position in its $4.3 billion US equity portfolio. This holding originated from Harvard’s early investment in SpaceX through venture capital funds, and the position has significantly appreciated after SpaceX’s public listing in June this year. The University of California also disclosed a roughly $1 billion position in SpaceX during the same period. Over the past decade, endowment funds from several universities have made substantial bets on private tech assets.